Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.60 |
| ▸ | JAK2 | O60674 | 8/20 | 0.60 |
| ▸ | JAK1 | P23458 | 6/20 | 0.60 |
| ▸ | TYK2 | P29597 | 2/20 | 0.54 |
| ▸ | STAT6 | P42226 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | BLK | P51451 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CCND2 | P30279 | 1/20 | 0.49 |
| ▸ | CCND3 | P30281 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21846884 | 1.00 | JAK3 (0.60) | JAK3JAK2JAK1TYK2STAT6 | |
| SCHEMBL29387810 | 0.92 | JAK3 (0.55) | JAK3JAK2JAK1TYK2STAT6 | |
| SCHEMBL21846885 | 0.92 | JAK3 (0.55) | JAK3JAK2JAK1TYK2STAT6 | |
| SCHEMBL28364470 | 0.91 | JAK3 (0.60) | JAK3JAK2JAK1TYK2STAT6 | |
| SCHEMBL21846883 | 0.91 | JAK3 (0.60) | JAK3JAK2JAK1TYK2STAT6 | |
| SCHEMBL29387805 | 0.91 | JAK3 (0.60) | JAK3JAK2JAK1TYK2STAT6 | |
| SCHEMBL21846878 | 0.90 | JAK3 (0.68) | JAK3JAK2JAK1TYK2STAT6 | |
| SCHEMBL29387386 | 0.90 | JAK3 (0.68) | JAK3JAK2JAK1TYK2STAT6 | |
| SCHEMBL24249375 | 0.86 | JAK3 (0.50) | JAK3JAK2JAK1EGFRFLT3 | |
| SCHEMBL21847332 | 0.85 | JAK3 (0.46) | JAK3JAK2JAK1STAT6EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993603-B2 | Preparation for 6-amino-1H-pyrazolo[3,4-d]pyrimidine-based JAK kinase inhibitor and application thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE (CN) | 2024-05-28 | — | — | US | disclosed |
| US-20220048914-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048914-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | JAK1, JAK3, SSB | JAK3 2/4885JAK2 5/4885JAK1 1/4885 |
| US-11993603-B2 | Preparation for 6-amino-1H-pyrazolo[3,4-d]pyrimidine-based JAK kinase inhibitor and application thereof | JAK1, JAK3, SSB | JAK3 2/4885JAK2 5/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.